How Will Baxter (BAX) Stock React to Q2 Earnings on Tuesday?

Baxter (BAX) is scheduled to report its 2016 second quarter results before Tuesday’s market open.
By Kaya Yurieff ,

NEW YORK (TheStreet) -- Shares of Baxter Int'l (BAX) - Get Report are declining 0.46% to $46.08 on Monday afternoon ahead of the company's 2016 second quarter earnings due out before Tuesday's opening bell.

Wall Street is expecting the Deerfield, IL-based healthcare products company to report earnings of 40 cents per share on revenue of $2.52 billion.

During the same quarter last year, Baxter said adjusted earnings were $1 per share on revenue of $3.9 billion.

The company provides a portfolio of renal and hospital products, including home, acute and in-center dialysis, sterile IV solutions, biosurgery products and anesthetics.

Separately, TheStreet Ratings Team has a "Buy" rating with a score of A- on the stock.

The company's strengths can be seen in multiple areas, such as its solid stock price performance, compelling growth in net income, largely solid financial position with reasonable debt levels by most measures, notable return on equity and attractive valuation levels.

The team believes its strengths outweigh the fact that the company shows weak operating cash flow.

Recently, TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author.

You can view the full analysis from the report here: BAX

Loading ...